HAEMATO AG |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.9 EUR | 0.00% |
|
-0.88% | 0.00% |
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.26 for the 2023 fiscal year.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company sustains low margins.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| 0.00% | 97.92M | - | ||
| +17.03% | 9.11B | A- | ||
| -24.00% | 4.44B | A- | ||
| +13.37% | 4.24B | B- | ||
| +31.17% | 4.03B | - | ||
| +7.68% | 2.14B | B | ||
| -34.04% | 1.9B | C- | ||
| +7.56% | 1.94B | - | - | |
| -0.50% | 1.64B | - | - | |
| -47.93% | 1.63B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- HAEK Stock
- Ratings HAEMATO AG
